Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in D-A-CH has been experiencing steady growth over the past few years. With an increasing number of cancer cases in the region, the demand for oncology drugs has been on the rise.
Customer preferences: Patients in D-A-CH are increasingly seeking personalized treatments that are tailored to their specific needs. This has led to the development of targeted therapies that are designed to treat specific types of cancer. Additionally, there is a growing preference for oral medications over traditional intravenous treatments.
Trends in the market: One of the major trends in the Oncology Drugs market in D-A-CH is the increasing use of immunotherapies. These treatments work by boosting the body's immune system to fight cancer cells. Another trend is the development of biosimilars, which are cheaper versions of existing biologic drugs. These drugs are expected to play a significant role in reducing healthcare costs.
Local special circumstances: Germany is the largest market for Oncology Drugs in D-A-CH, accounting for more than half of the region's total market share. The country has a well-established healthcare system and is home to several leading pharmaceutical companies. Switzerland is another important market, with a strong focus on research and development.
Underlying macroeconomic factors: The aging population in D-A-CH is a major driver of the Oncology Drugs market. As people age, they are more likely to develop cancer, leading to an increased demand for oncology drugs. Additionally, the region's strong economy and high healthcare spending have contributed to the growth of the market. However, increasing pressure to reduce healthcare costs could pose a challenge to the market's growth in the future.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
